A health ministry panel Wednesday approved a plan to cut the price of Lecanemab, an Alzheimer's drug codeveloped by Japanese ...

Four years of lecanemab treatment led to less cognitive decline and potentially even improvement in clinical scores over time, with a favorable safety profile, in the open-label extension trial.

Differences in outcomes between patients with early Alzheimer’s disease who used lecanemab and matched controls increased ...

Lecanemab and donanemab effects lasting over three years, new treatments, trials of home injections and blood tests for ...

Lecanemab is a monoclonal antibody with high affinity to amyloid-beta soluble protofibrils. It was approved in 2023 as an IV ...

日本の製薬大手エーザイが共同開発したアルツハイマー病の治療薬「レカネマブ（Lecanemab）」が、米食品医薬品局（FDA）から正式承認された ...

Lecanemab may be safe and effective for treating early-stage Alzheimer’s disease within a small community of older adults, ...

Lecanemab’s PDUFA* date for its potential accelerated approval is January 6th. The product could launch after its approval by the Food and Drug Administration (FDA).

The US Food and Drug Administration has granted traditional approval to Eisai and Biogen’s Alzheimer’s therapy lecanemab, making the drug the first in its class to fully gain the green light ...

Lecanemab, the disease-modifying drug which can slow down the progression of Alzheimer’s disease, is set to be one of the most sought-after medications in the country after UK regulators ...

Lecanemab and Aduhelm are part of a class of drugs called monoclonal antibodies, and the agency that oversees Medicare has said it will only pay for this type of Alzheimer’s drug for patients ...

By that point, the lecanemab cohort’s average amyloid level had dropped by 55.48 centiloids and the placebo group had increased by 3.64 centiloids. The confirmatory trial’s results suggest that ...